#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Astrocytoma Squamous cell carcinoma of head and neck Marginal zone lymphoma Congenital pseudarthrosis Neurotrophic keratopathy Warm autoimmune haemolytic anaemia Deafness neurosensory Oesophageal adenocarcinoma stage II Atopic keratoconjunctivitis Cataract Crohn's disease Neuroendocrine cell hyperplasia of infancy Thalassaemia alpha Cutaneous T-cell lymphoma recurrent Diffuse large B-cell lymphoma More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment Mucopolysaccharidosis III – Treatment Thrombotic thrombocytopenic purpura – Diagnostics Pleural mesothelioma malignant – Basic Information Haemophilia B with anti factor IX – Life with Disease Epidermolysis bullosa – Treatment Acquired haemophilia Pituitary-dependent Cushing’s syndrome – Treatment Testicular leiomyosarcoma – Diagnostics Ewing’s sarcoma metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Esk-001 Oxitriptan Alternaria Alternata Extract Auto4 Gimeracil Abc-23B-116 Ofloxacin Mva-209-Fsp-B2 Carboplatin Phenprocoumon Cobimetinib Prs-344 Navtemadlin Ioversol Hct116-A Treosulfan Pivekimab Sunirine Tarlatamab Etravirine 64Cu-Dota-Ae105 More therapies…

    Learn about Your Condition

    Sexual dysfunction Bipolar disorder Muscle injury Retinoblastoma Head and neck cancer stage IV Bile duct cancer Cartilage injury Bile acid synthesis disorder Breast cancer Choroidal neovascularisation Deep vein thrombosis Hypothyroidism Colon cancer stage IV Cytomegalovirus infection Alpha-1 antitrypsin deficiency More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab
    Spain

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    • Leuprorelin
    Austria Belgium Finland France Germany Greece +7

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Anastrozole
    • Anhydrous Docetaxel
    Belgium France Germany Hungary Italy Poland +2

  • Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Metformin
    • Alpelisib
    • Inavolisib
    Belgium France Germany Italy Poland Spain

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor negative HER2 positive breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Antiemetics And Antinauseants
    • Antipsychotics
    • Corticosteroids, Plain
    Austria Belgium Czechia France Germany Greece +5

  • Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Abemaciclib
    Spain
Previous Page
1 … 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!